Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Top Cited Papers
- 10 November 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (32), 8253-8261
- https://doi.org/10.1200/jco.2005.03.4777
Abstract
Prostate cancers that are progressing on medical and surgical therapies designed to ablate the action of androgens continue to express androgen receptor (AR) and to depend on signaling through the ...This publication has 97 references indexed in Scilit:
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2005
- Negative Modulation of Androgen Receptor Transcriptional Activity by DaxxMolecular and Cellular Biology, 2004
- Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular eventsMolecular Carcinogenesis, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Novel Therapeutic Molecular Targets for Prostate Cancer: The mTor Signaling Pathway and Epidermal Growth Factor ReceptorJournal of Urology, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Hsp90 as a therapeutic target in prostate cancerSeminars in Oncology, 2003
- Establishment of Short-Term Primary Human Prostate Xenografts for the Study of Prostate Biology and CancerThe American Journal of Pathology, 2001
- Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotidesCancer Gene Therapy, 2000
- Estrogens in the Treatment of Prostate CancerJournal of Urology, 1995